focus -WSS

focus

author：explore 2025-09-30 23:11:03 - browse：7

There are a lot of reasons why updated data on Pfizer’s Lorbrena, a treatment for non-small cell lung cancer, might not seem to be a big deal. The results are an update on the clinical trial that resulted in the Food and Drug Administration granting Lorbrena full approval in 2001, so in a sense they are not even that new. For Pfizer investors, Lorbrena isn’t that big a deal, either. The medicine, for patients whose lung tumors have particular genetic mutations, generated only $575 million last year — an amount that is up 57% from the year prior, but that still constitutes only 1% of the drug giant’s annual sales.

But there is one number that makes the Lorbrena data quite eye-catching: In the updated data, the daily pill decreased the risk that cancer would progress or that a patient would die by 81% over five years.

That’s a stunning number, especially when one considers that Lorbrena was not being compared to an inert placebo but to Xalkori, another Pfizer targeted cancer drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： FDA approves Recor Medical high blood pressure device

focus

WSS

More doctors should go into startup world

More doctors should go into startup world

Alzheimer's risk factor APOE4 may be a distinct form of the disease

Senate panel clears PBM, hopsital reforms

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

UCSF medical school apologizes for unethical prisoner experiments

knowledge

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Moonlake's readout produced a cash windfall. Risks remain

Drug companies' payments and gifts affect physicians' prescribing

As demand for Covid shots wanes, Moderna seeks its next success

FDA approves potent Eli Lilly obesity drug, Zepbound

Duchenne breakthrough therapy leaves behind pioneering families

Young boy dies in trial for Pfizer Duchenne gene therapy

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Executive Editor Rick Berke on STAT's 8th birthday

In Memoriam: Notable people who died in 2023

Biotech incubator Curie.Bio graduates its first startup

hotspot

Bird flu reported in person exposed to presumably infected cattle

Covid silver lining: Unprecedented look at human immune system

Extreme heat events are a public health emergency

Multiple sclerosis has subtypes with different best treatments: study

Will General Catalyst be the first of many hospital takeovers?

Medicare solvency divides Republicans at the presidential debate

focus

focus

entertainment

focus